CA2381319A1 - Molecules utilisees a des fins diagnostiques et therapeutiques - Google Patents

Molecules utilisees a des fins diagnostiques et therapeutiques Download PDF

Info

Publication number
CA2381319A1
CA2381319A1 CA002381319A CA2381319A CA2381319A1 CA 2381319 A1 CA2381319 A1 CA 2381319A1 CA 002381319 A CA002381319 A CA 002381319A CA 2381319 A CA2381319 A CA 2381319A CA 2381319 A1 CA2381319 A1 CA 2381319A1
Authority
CA
Canada
Prior art keywords
cell
proteins
polynucleotide
protein
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002381319A
Other languages
English (en)
Inventor
David M. Hodgson
Stephen E. Lincoln
Frank D. Russo
Peter A. Spiro
Steven C. Banville
Shawn R. Bratcher
Gerard E. Dufour
Howard J. Cohen
Bruce H. Rosen
Michael S. Chalup
Jennifer L. Hillman
Anissa L. Jones
Jimmy Y. Yu
Lila B. Greenawalt
Scott R. Panzer
Ann M. Roseberry
Rachel J. Wright
Susan E. Daniels
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2381319A1 publication Critical patent/CA2381319A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention se rapporte à des polynucléotides humains purifiés utilisés à des fins diagnostiques et thérapeutiques (dithp). Elle se rapporte également aux polypeptides (DITHP) codés par ces dithp. Elle se rapporte également à l'utilisation de ces dithp, ou de leurs compléments, oligonucléotides ou fragments dans des analyses diagnostiques. L'invention se rapporte en outre à des vecteurs et cellules hôtes contenant ces dithp et permettant l'expression de DITHP. Elle concerne notamment l'utilisation de tels DITHP isolés et purifiés pour induire des anticorps et pour analyser des banques de composés ainsi que l'utilisation des anticorps anti-DITHP dans des analyses diagnostiques. L'invention se rapporte à des micro-ensembles contenant des dithp et à leur procédés d'utilisation.
CA002381319A 1999-06-01 2000-05-31 Molecules utilisees a des fins diagnostiques et therapeutiques Abandoned CA2381319A1 (fr)

Applications Claiming Priority (49)

Application Number Priority Date Filing Date Title
US13716199P 1999-06-01 1999-06-01
US60/137,161 1999-06-01
US13726099P 1999-06-02 1999-06-02
US13711399P 1999-06-02 1999-06-02
US13725999P 1999-06-02 1999-06-02
US13710999P 1999-06-02 1999-06-02
US13725899P 1999-06-02 1999-06-02
US13711499P 1999-06-02 1999-06-02
US13717399P 1999-06-02 1999-06-02
US60/137,114 1999-06-02
US60/137,109 1999-06-02
US60/137,113 1999-06-02
US60/137,260 1999-06-02
US60/137,259 1999-06-02
US60/137,173 1999-06-02
US60/137,258 1999-06-02
US13739699P 1999-06-03 1999-06-03
US13741199P 1999-06-03 1999-06-03
US13733799P 1999-06-03 1999-06-03
US13741799P 1999-06-03 1999-06-03
US60/137,396 1999-06-03
US60/137,411 1999-06-03
US60/137,337 1999-06-03
US60/137,417 1999-06-03
US14743699P 1999-08-04 1999-08-04
US14737799P 1999-08-04 1999-08-04
US60/147,377 1999-08-04
US60/147,436 1999-08-04
US14752099P 1999-08-05 1999-08-05
US14752799P 1999-08-05 1999-08-05
US14750099P 1999-08-05 1999-08-05
US14754199P 1999-08-05 1999-08-05
US14782499P 1999-08-05 1999-08-05
US14754299P 1999-08-05 1999-08-05
US14754999P 1999-08-05 1999-08-05
US14753699P 1999-08-05 1999-08-05
US14753099P 1999-08-05 1999-08-05
US14754799P 1999-08-05 1999-08-05
US60/147,824 1999-08-05
US60/147,542 1999-08-05
US60/147,547 1999-08-05
US60/147,500 1999-08-05
US60/147,527 1999-08-05
US60/147,549 1999-08-05
US60/147,530 1999-08-05
US60/147,536 1999-08-05
US60/147,520 1999-08-05
US60/147,541 1999-08-05
PCT/US2000/015404 WO2000073509A2 (fr) 1999-06-01 2000-05-31 Molecules utilisees a des fins diagnostiques et therapeutiques

Publications (1)

Publication Number Publication Date
CA2381319A1 true CA2381319A1 (fr) 2000-12-07

Family

ID=27586737

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002381319A Abandoned CA2381319A1 (fr) 1999-06-01 2000-05-31 Molecules utilisees a des fins diagnostiques et therapeutiques

Country Status (3)

Country Link
EP (1) EP1268758A2 (fr)
CA (1) CA2381319A1 (fr)
WO (1) WO2000073509A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025191A (en) * 1995-06-07 2000-02-15 Ludwig Institute For Cancer Research Isolated nucleic acid molecules which encode a melanoma specific antigen and uses thereof
AU2001236519A1 (en) * 2000-01-24 2001-07-31 Millennium Pharmaceuitcals, Inc. Identification, assessment, prevention, and therapy of prostate cancer
AU2001243283A1 (en) * 2000-02-25 2001-09-03 Millennium Pharmaceuticals, Inc. 44576, a novel g-protein coupled receptor and uses therefor
WO2001066765A2 (fr) * 2000-03-07 2001-09-13 Millennium Pharmaceuticals, Inc. 26583, nouvelle serine/threonine phosphatase et utilisations correspondantes
US7611892B2 (en) 2000-03-24 2009-11-03 President And Fellows Of Harvard College Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
US7189565B2 (en) 2001-03-23 2007-03-13 Fahri Saatcioglu Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
AU4941101A (en) * 2000-03-24 2001-10-08 Fahri Saatcioglu Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides,and diagnostic and therapeutic methods
WO2001077339A1 (fr) * 2000-04-07 2001-10-18 Merck Patent Gmbh Phosphatase deshydrogenese pyruvate humaine
WO2002064792A2 (fr) * 2001-01-05 2002-08-22 Incyte Genomics, Inc. Molecules utiles pour detecter et traiter des maladies
WO2002055738A2 (fr) * 2001-01-12 2002-07-18 Incyte Genomics Inc Molecules pour la detection et le traitement de maladies
WO2004016733A2 (fr) 2002-08-16 2004-02-26 Agensys, Inc. Acides nucleiques et proteines correspondantes connues sous 251p5g2 que l'on utilise dans le traitement et la detection de cancers
AU2003287424A1 (en) * 2002-11-01 2004-06-07 Case Western Reserve University Methods of inhibiting glial scar formation
EP1652923B1 (fr) 2003-08-08 2011-10-12 Perseus Proteomics Inc. Gene surexprime dans le cancer
CN111269944A (zh) * 2020-02-05 2020-06-12 青岛大学 一种小鼠白内障动物模型及其应用
CN115725733B (zh) * 2022-08-10 2023-11-14 人和未来生物科技（长沙）有限公司 一种znf135基因甲基化检测试剂及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6114114A (en) * 1992-07-17 2000-09-05 Incyte Pharmaceuticals, Inc. Comparative gene transcript analysis
AU2582897A (en) * 1996-03-15 1997-10-01 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
EP0948531A1 (fr) * 1996-12-11 1999-10-13 Chiron Corporation Proteines humaines secretees
JP2001526546A (ja) * 1997-06-11 2001-12-18 アボツト・ラボラトリーズ 肺の疾患の検出に有用な試薬および方法
JP3964982B2 (ja) * 1997-06-19 2007-08-22 生化学工業株式会社 ヘパラン硫酸６−ｏ硫酸基転移酵素のポリペプチド及びそれをコードするｄｎａ
AU8203598A (en) * 1997-07-11 1999-02-08 Mount Sinai Hospital Corporation Methods for identifying genes expressed in selected lineages, and a novel genes identified using the methods

Also Published As

Publication number Publication date
EP1268758A2 (fr) 2003-01-02
WO2000073509A3 (fr) 2001-04-26
WO2000073509A2 (fr) 2000-12-07

Similar Documents

Publication Publication Date Title
CA2442705A1 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
WO2004023973A2 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
US20040115629A1 (en) Molecules for diagnostics and therapeutics
CA2381319A1 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
Rhodes et al. The 52 000 MW Ro/SS‐A autoantigen in Sjögren's syndrome/systemic lupus erythematosus (Ro52) is an interferon‐γ inducible tripartite motif protein associated with membrane proximal structures
US20040014087A1 (en) Molecules for diagnostics and therapeutics
US20080206261A1 (en) Methods for screening, treating and diagnosing inflammatory bowel disease and compositions thereof
Rauch et al. Crispr-Cas9 engineered osteogenesis imperfecta type V leads to severe skeletal deformities and perinatal lethality in mice
Laurent et al. Biosynthesis of proopiomelanocortin-derived peptides in prohormone convertase 2 and 7B2 null mice
US20080085323A1 (en) Product and Methods for Diagnosis and Therapy for Cardiac and Skeletal Muscle Disorders
Seth et al. Coordinate expression of novel genes during osteoblast differentiation
Shao et al. Cell and molecular regulation of endothelin-1 production during hepatic wound healing
WO2021183218A1 (fr) Compositions et procédés de modulation de l'interaction entre l'oncoprotéine de fusion ss18-ssx et les nucléosomes
JP6669501B2 (ja) 皮膚の色素沈着を減少する組成物及び方法
US20040048253A1 (en) Molecules for diagnostics and therapeutics
JPH11502402A (ja) レチノイドｘ受容体相互作用性ポリペプチドならびに関連する分子および方法
Chen et al. Identification of novel DYNC2H1 mutations associated with short rib-polydactyly syndrome type III using next-generation panel sequencing
WO2003062376A2 (fr) Molécules pour le diagnostic et la thérapeutique
Sharman et al. Deciphering the mechanisms of homeostatic plasticity in the hypothalamo-neurohypophyseal system—genomic and gene transfer strategies
WO2001062927A2 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
CA2421265A1 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
JPWO2007000884A1 (ja) 骨・関節疾患の予防・治療剤およびそのスクリーニング方法
CA2401868A1 (fr) Molecules utilisees a des fins diagnostiques et therapeutiques
AU2004223739B2 (en) Cyclic AMP response element activator proteins and uses related thereto
US20120060231A1 (en) Method and kit for evaluation of predisposition to development of obesity, anti-obesity agent and method for screening thereof, non-human animal, adipose tissue, adipocyte, method for production of transgenic mouse, antigen, and antibody

Legal Events

Date Code Title Description
FZDE Discontinued